Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 3, Mars 2002
Page(s) 343 - 352
Section M/S Revues : Articles de Synthèse
DOI https://doi.org/10.1051/medsci/2002183343
Publié en ligne 15 mars 2002
  1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 226 : 347–56. [Google Scholar]
  2. Thomas HC, Törok ME, Forton DM, et al. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999; 32 (suppl 1) : 152–9. [Google Scholar]
  3. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282 : 103–7. [Google Scholar]
  4. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6 : 1375–9. [Google Scholar]
  5. Hultgren C, Milich DR, Weiland O, et al. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79 : 2381–91. [Google Scholar]
  6. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med 1997; 127 : 875–81. [Google Scholar]
  7. Duchatelle V, Marcellin P, Giostra E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assement by a morphometric method. J Hepatol 1998; 29 : 20–8. [Google Scholar]
  8. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon : a preliminary report. N Engl J Med 1986; 315 : 1575–8. [Google Scholar]
  9. Marcellin P. Traitement de l’hépatite C par l’interféron. Conférence de Consensus - Textes des experts. Comment traiter l’hépatite C ? Gastroenterol Clin Biol 1997; 20 : S81–S88. [Google Scholar]
  10. Shiffman ML. Use of highdose interferon in the treatment of chronic hepatitis C. Sem Liver Dis. 1999; 19 (Suppl 1) : 25–33. [Google Scholar]
  11. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352 : 1426–32. [Google Scholar]
  12. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339 : 1485–92. [Google Scholar]
  13. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956–61 [Google Scholar]
  14. Boyer N, Marcellin P. L’interféron pegylé : nouveau progrès dans le traitement de l’hépatite chronique C. Gastroentérol Clin Biol 2000; 24 : 767–9. [Google Scholar]
  15. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343 : 1666–72. [Google Scholar]
  16. Lindsay KL, Trépo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34 : 395–403 [Google Scholar]
  17. Manns MP, McHutchison JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with IFN-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial. Lancet 2001; 358 : 958–65. [Google Scholar]
  18. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin : efficacy and safety results from a phase III, randomized, activelycontrolled, multicenter study. Gastroenteroly 2001; 120 : A55 (abstract). [Google Scholar]
  19. Chow WC, Boyer N, Pouteau M, et al. Retreatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998; 27 : 1144–8. [Google Scholar]
  20. Pol S, Couzigou P, Bourlière M, et al. A randomized trial of ribavirin and interferon-a vs, interferon-a alone in patients with chronic hepatitis C who were nonresponders to a previous treatment. J Hepatol 1999; 31 : 1–7. [Google Scholar]
  21. Brillanti S, Levantesi F, Masi L, et al. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32 : 630–4. [Google Scholar]
  22. Wright M, main J, Thomas HC. Drug-resistant viral hepatitis. J Infect 2000; 41 : 1–4. [Google Scholar]
  23. Valla D, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis. A randomized controlled trial of IFN-2b versus non treatment. Hepatology 1999; 29 : 1870–5. [Google Scholar]
  24. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis : analysis of individual patient data of six controlled trials. Gastroenterology 1999; 117 : 408–13. [Google Scholar]
  25. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346 : 1051–5. [Google Scholar]
  26. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C : a retrospective followup study of 384 patients. Gastroenterology 1997; 112 : 463–72. [Google Scholar]
  27. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronichepatitis C in Japan. Ann Intern Med 1999; 131 : 174–81. [Google Scholar]
  28. Marcellin P. Hepatitis C : the clinical spectrum of the disease. J Hepatol 1999; 31 : (suppl 1) : 9–16. [Google Scholar]
  29. Marcellin P, Lévy S, Erlinger S. Treatment of patients with chronic HCV infection with normal serum ALT levels. Hepatology 1997; 26 (suppl 1) : 133S–136S. [Google Scholar]
  30. Poynard T. Quelles sont les indications du traitement dans l’hépatite aiguë C ? Gastroenterol Clin Biol 1997; 21 : S66–S69. [Google Scholar]
  31. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345 : 1452–7. [Google Scholar]
  32. Gervais A, Boyer N, Marcellin P. Co-infection VIH-VHC en l’an 2001. La lettre de l’infectiologue 2001; Tome XVI, N° 6 : 186–90. [Google Scholar]
  33. Causse X, Payen JL, Izopet J, Babany G, Saint Marc Girardin MF and the French Multicenter Study Group. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment ? A French multicenter prospective study. J Hepatol 2000; 32: 1003–10. [Google Scholar]
  34. Landau A, Batisse D, Duong Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-a 2b and ribavirin for chronic hepatitis C in HIV infected patients. AIDS 2000; 14 : 839–44. [Google Scholar]
  35. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferonribavirin combination therapy in HCV-HIV coinfected subjects : an early report. Gut 2000; 47 : 608–9. [Google Scholar]
  36. Féray C, Caccamo L, Alexander GJM, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C.Gastroenterology 1999; 117 : 619–25. [Google Scholar]
  37. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of alpha interferon and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26 : 500–504. [Google Scholar]
  38. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France : relationship with epidemiology, pathogenicity and response to interferon therapy J Viral Hepatitis 1999; 6 : 435–43. [Google Scholar]
  39. Martinot-Peignoux M, Boyer N, Pouteau M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29 : 214–23. [Google Scholar]
  40. Gervais A, Boyer B, Marcellin P. Tolerability of treatments for viral hepatitis. In Drug Safety. Ed. Adis international Ltd, Auckland, New Zealand, Vol. 24, N° 5, 2001 pp375–384. [Google Scholar]
  41. Asselah T, Martinot M, Boyer N, et al. Variabilité génétique du virus de l’hépatite C : implications cliniques. Gastroenterol Clin Biol 2000; 24 : 175–84. [Google Scholar]
  42. Pawlotsky JM, Pellerin M, Bouvier M, et al. Genetic complexity of the hypervariable region 1 (HVR 1) of hepatitis C virus. Influence on the characteristics of the infection and the response to alpha-interferon therapy in patients with chronic hepatitis C. J Med Virol 1998; 54 : 256–64. [Google Scholar]
  43. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the non structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334 : 77–81. [Google Scholar]
  44. Gervais A, Martinot M, Boyer N, et al. Quantitation of hepatic hepatitis C virus RNA with chronic hepatitis C, relationship with severity of disease, viral genotype and response to treatment. J Hepatol 2001; 35 : 399–405. [Google Scholar]
  45. Love RA, Parge HE, Wickersham JA, et al. The crystal structure of hepatits C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87 : 331–42. [Google Scholar]
  46. Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4 : 463–7. [Google Scholar]
  47. Von Weizsacker F, Wieland S, Kock J, et al. Gene therapy for chronic viral hepatitis : ribozymes antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26 : 251–5 [Google Scholar]
  48. Abrignani S, Houghton M, Hsu HH. Perspective for a vaccine against hepatitis C virus. J Hepatol 1999; 31 : 259–263. [Google Scholar]
  49. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91 : 1294–8. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.